|Bid||73.42 x 373700|
|Ask||73.44 x 1281100|
|Day's range||73.30 - 74.20|
|52-week range||72.96 - 88.30|
|PE ratio (TTM)||21.53|
|Earnings date||18 Jul 2018|
|Forward dividend & yield||2.80 (3.79%)|
|1y target est||88.59|
Incyte (INCY) reports positive results on Jakafi from the REACH trial for the indication of acute GVHD. The company plans to file a sNDA for the drug in the third quarter.
Novartis AG (VTX:NOVN) is a company with exceptional fundamental characteristics. Upon building up an investment case for a stock, we should look at various aspects. In the case of NOVN,Read More...
PTC Therapeutics shares are spiking following intriguing trial data; however, it's not the only competitor working on better treatments for SMA.
The S&P 500’s top losses on June 18 were: Biogen (BIIB) declined 5.2%. Comcast Corp A (CMCSA) declined 3.8%. AmerisourceBergen (ABC) declined 3.5%. Intel (INTC) declined 3.4%. CVS (CVS) declined 3.4%. Biogen
Novartis (NVS) announces positive results on Kymriah from the JULIET TRIAL in patients with relapsed or refractory diffuse large B-cell lymphoma.
Over the past 10 years Novartis AG (NYSE:NVS) has returned an average of 4.00% per year from dividend payouts. The company is currently worth US$191.86B, and now yields roughly 3.71%.Read More...
Federal prosecutors in Manhattan are investigating whether Michael Cohen, the longtime personal lawyer for Donald Trump, illegally engaged in secret lobbying, people familiar with the investigation said, as part of the government’s broader probe into Mr. Cohen’s business dealings. In the course of that investigation, the prosecutors have contacted companies that hired Mr. Cohen as a consultant after Mr. Trump won the 2016 presidential election, including AT&T Inc. and Novartis AG, according to other people familiar with the matter.
Can online access to mental health care improve the lives of patients with schizophrenia and multiple sclerosis? Swiss drug giant Novartis and its executive director of digital therapeutics, Joris Van Dam, say yes.
26 abstracts on Cosentyx ® (secukinumab) in ankylosing spondylitis (AS) and psoriatic arthritis (PsA) will be presented at the Annual European Congress of Rheumatology (EULAR 2018 ) Breadth of data ...
Merck (MRK) steals the limelight at ASCO with a key lung cancer data presentation. Lilly (LLY) gains FDA nod for the lower dose of its rheumatoid arthritis candidate, Olumiant.
Patients reported prolonged maintenance of global health status(overall health) Longer time to deterioration (TTD) seen across multiple clinically relevant symptom categories including diarrhea, fatigue ...
Although other companies, including AT&T, also paid Mr. Cohen for his services, Novartis is distinguished for likely having paid more than any of the others, and it drew the attention of prosecutors at home.
The U.S. Treasury Department has refused to respond to Senator Ron Wyden’s request for financial details related to payments that Swiss drugmaker Novartis AG made to Donald Trump’s lawyer Michael Cohen, a spokeswoman for the Democratic lawmaker said. Novartis is cooperating fully and provided “substantial” responses to the letter Wyden sent the company’s chief executive last month as part of a Senate Finance Committee review, according to an email from the Oregon senator’s office Wednesday.
Switzerland’s top prosecutor won’t open criminal proceedings against Novartis AG over payments the Basel-based drugmaker made to Michael Cohen, the troubled lawyer for Donald Trump. After an in-depth analysis, the Office of the Attorney-General decided there was “insufficient suspicion to justify opening criminal proceedings” it said in a statement on Wednesday. The Swiss prosecutors said they consulted with the Basel Prosecutor’s Office in Novartis’s hometown, and failed to find sufficient grounds to proceed with charges into the allegations of bribery of a foreign public official or private individual.
The Swiss attorney general's office (OAG) said on Wednesday it will not bring proceedings against Novartis in connection with $1.2 million in payments the Swiss drugmaker made to U.S. President Donald Trump's personal lawyer. The OAG had received a criminal complaint alleging bribery of foreign public officials by Novartis, which has said it struck a year-long contract with Trump lawyer Michael Cohen in 2017 to gain insights into the administration's thinking on healthcare issues. Novartis has since called the pact a mistake.
The Swiss attorney general's office (OAG) said on Wednesday it will not bring proceedings against Novartis (NOVN.S) in connection with $1.2 million in payments the Swiss drugmaker made to U.S. President Donald Trump's personal lawyer. The OAG had received a criminal complaint alleging bribery of foreign public officials by Novartis, which has said it struck a year-long contract with Trump lawyer Michael Cohen in 2017 to gain insights into the administration's thinking on healthcare issues. Novartis has since called the pact a mistake.
Kisqali plus fulvestrant demonstrated superior efficacy, with a median PFS of 20.5 months vs. 12.8 months for fulvestrant alone, among overall study population of first- and second-line postmenopausal ...
ENESTop and ENESTfreedom data evaluate Treatment-free Remission (TFR) rates at 144 weeks among eligible Ph+ CML-CP patients who stopped Tasigna ® Findings further support durability and safety of TFR ...
Novartis is one step closer to taking a bite out of AbbVie's blockbuster arthritis drug after a European committee recommended officials approve its Humira biosimilar on Friday.
With (Other OTC: WWTH - news) women hardest hit by migraine headaches, Swiss drugmaker Novartis is gearing up its marketing message to counteract sexism that it worries might become a barrier to adoption of its new medicine Aimovig. The injectable monoclonal antibody that Novartis has developed with Amgen (NasdaqGS: AMGN - news) won approval in the United States this month and on Friday bagged a recommendation from a key European panel, clearing the way for likely approval on the continent. Novartis is also considering new pricing models for Aimovig.
Novartis's (NOVN.S) generics unit on Friday won a European panel's recommendation for its biosimilar version of AbbVie's (ABBV.N) Humira as the Swiss drugmaker aims to take a bite out of sales of one of the world's best-selling medicines. The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion for marketing authorisation of Novartis's proposed biosimilar adalimumab. The European Commission nearly always follows the CHMP recommendation.